VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Male and female patients between the ages of 18-65 │ Male and female patients between the ages of 18-65 │     100 │
│ years, inclusive                                   │ years, inclusive                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients (or legal representative) willing and     │ Patients (or legal representative) willing and     │     100 │
│ able to provide written Informed Consent Form      │ able to provide written Informed Consent Form      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Psychiatric patients already diagnosed of          │ Psychiatric patients already diagnosed of          │     100 │
│ schizophrenia or bipolar disorder, according to    │ schizophrenia or bipolar disorder, according to    │         │
│ the Diagnostic and Statistical Manual of Mental    │ the Diagnostic and Statistical Manual of Mental    │         │
│ Disorders- IV, Diagnostic and Statistical Manual   │ Disorders- IV, Diagnostic and Statistical Manual   │         │
│ of Mental Disorders- V or International Code of    │ of Mental Disorders- V or International Code of    │         │
│ Disease criteria                                   │ Disease criteria                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with an on-going agitation episode, or    │ Patients with an on-going agitation episode, or    │     100 │
│ with a previous one within the 6 months prior to   │ with a previous one within the 6 months prior to   │         │
│ screening, attended and managed in the hospital    │ screening, attended and managed in the hospital    │         │
│ setting                                            │ setting                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previously treated with ADASUVE® with a positive   │ Previously treated with ADASUVE® with a positive   │     100 │
│ outcome (responders) according to (CGI-I) scale    │ outcome (responders) according to (CGI-I) scale    │         │
│ (defined as having a CGI-I score of 1 or 2 at 2    │ (defined as having a CGI-I score of 1 or 2 at 2    │         │
│ hours after administration of the inhalation)      │ hours after administration of the inhalation)      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients free of active respiratory disease such   │ Patients free of active respiratory disease such   │     100 │
│ as acute respiratory signs/symptoms (e.g.,         │ as acute respiratory signs/symptoms (e.g.,         │         │
│ wheezing) or with active airways disease (asthma,  │ wheezing) or with active airways disease (asthma,  │         │
│ chronic obstructive pulmonary disease or           │ chronic obstructive pulmonary disease or           │         │
│ emphysema)                                         │ emphysema)                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Availability of patient's medical records data     │ Availability of patient's medical records data     │     100 │
│ about the previous treatment with ADASUVE® at      │ about the previous treatment with ADASUVE® at      │         │
│ hospital setting                                   │ hospital setting                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If a female is of childbearing potential and       │ If a female is of childbearing potential and       │     100 │
│ sexually active (except if female is surgically    │ sexually active (except if female is surgically    │         │
│ sterile or post-menopausal with history of no      │ sterile or post-menopausal with history of no      │         │
│ menses for at least 24 months), patient must be    │ menses for at least 24 months), patient must be    │         │
│ non-lactating and non-pregnant (with a negative    │ non-lactating and non-pregnant (with a negative    │         │
│ pregnancy test result at baseline visit) and have  │ pregnancy test result at baseline visit) and have  │         │
│ to agree to use a medically acceptable and         │ to agree to use a medically acceptable and         │         │
│ effective birth control method throughout the      │ effective birth control method throughout the      │         │
│ study and for one week following the end of the    │ study and for one week following the end of the    │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient diagnosed with dementia                    │ Patient diagnosed with dementia                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with serious and unstable illnesses       │ Patients with serious and unstable illnesses       │     100 │
│ including current hepatic, renal,                  │ including current hepatic, renal,                  │         │
│ gastroenterologic, respiratory, cardiovascular     │ gastroenterologic, respiratory, cardiovascular     │         │
│ (including ischemic heart disease and congestive   │ (including ischemic heart disease and congestive   │         │
│ heart failure), endocrinologic, neurologic         │ heart failure), endocrinologic, neurologic         │         │
│ (including stroke, transient ischemic attack,      │ (including stroke, transient ischemic attack,      │         │
│ subarachnoidal bleeding, brain tumor,              │ subarachnoidal bleeding, brain tumor,              │         │
│ encephalopathy, and meningitis)                    │ encephalopathy, and meningitis)                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a history of allergic reactions to   │ Patients with a history of allergic reactions to   │     100 │
│ loxapine or amoxapine                              │ loxapine or amoxapine                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have received an investigational drug │ Patients who have received an investigational drug │     100 │
│ within 30 days prior to the current agitation      │ within 30 days prior to the current agitation      │         │
│ episode must be excluded                           │ episode must be excluded                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are considered by the investigator,   │ Patients who are considered by the investigator,   │     100 │
│ for any reason, to be unable to self-administer    │ for any reason, to be unable to self-administer    │         │
│ the inhalation device                              │ the inhalation device                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Requirement of family or other caregiver support   │ Requirement of family or other caregiver support   │      99 │
│ at study investigator criteria (defined as a       │ at study investigator criteria (defined as a       │         │
│ patient's relative or caregiver (male or female) ≤ │ patient's relative or caregiver (male or female) = │         │
│ 80 year old, who spend ≥ 3 consecutive hours with  │ 80 year old, who spend = 3 consecutive hours with  │         │
│ patient, with good physical and psychological      │ patient, with good physical and psychological      │         │
│ health status and without physical limitations,    │ health status and without physical limitations,    │         │
│ reading and writing educational level and able to  │ reading and writing educational level and able to  │         │
│ understand and follow the study procedures)        │ understand and follow the study procedures)        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Male and female patients between the ages of 18-65 │      44 │
│                                   │ years, inclusive                                   │         │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 65 Years │ Male and female patients between the ages of 18-65 │      44 │
│                                   │ years, inclusive                                   │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 92.9375
OverAll Ratio: 95.96875
